3/17
  • Pages
  • Editions
01 Cover
02 Editor's Letter
03 Editorial Board
04 Contents
05 News
06 Gene editing bill: encouraging innovation or adding complexity?
07 All in the timing
08 Solving the PCT Priority problem
09 G 2/21: how to support inventive steps in patentability
10 A guide for life sciences entrepreneurs
11 The fall of COVID-19 and the rise of antimicrobial resistance
12 Predicting the unpredictable during pregnancy
13 Pandemic blues: the global approach to COVID-related IP
14 Psychedelics: from fungi and plants to patents
15 When alliances fail, is arbitration the answer?
16 Movers & Shakers
17 Contact us

EDITORIAL BOARD

MaryAnne Armstrong

Partner, Birch, Stewart, Kolasch & Birch

Benoît Beuken

Senior trademark counsel, UCB

Wolfgang Bublak

Partner, Bardehle Pagenberg

Trevor Cook

Partner, Wilmer Cutler Pickering Hale and Dorr

Gabriel Di Blasi

Partner, Di Blasi, Parente & Associados

Paul England

Senior associate, Taylor Wessing

Janis Fraser

Principal, Fish & Richardson

Gunars Gaikis

Senior counsel, Norton Rose Fulbright

Penny Gilbert

Partner, Powell Gilbert

Andrew Jenner

Director of IP, innovation and trade, International Federation of Pharmaceutical Manufacturers and Associations

Ashwin Julka

Managing partner, Remfry & Sagar

Lars Kellberg

Corporate vice-president and chief patent counsel, Novo Nordisk

Judith Kim

Partner, Rubin and Rudman

Simon Kremer

Partner, Mewburn Ellis

Nathalie Moll

Secretary general, EuropaBio

Matthew Nielsen

Partner, Marshall Gerstein & Borun

Michael Pitzner-Bruun

Head of legal affairs, Evolva

Jason Rutt

Patent attorney, Boult Wade Tennant

Jose Trigueros

Partner, Leyva Montenegro Trigueros Abogados

Joachim Wachenfeld

Partner, Vossius & Partner

Jane Wainwright

Partner, Potter Clarkson

Franz-Josef Zimmer

Patent attorney, Grünecker

Issue 1, 2022


Stay up to date with the latest news

SUBSCRIBE HERE